Lancet, The, ISSN 0140-6736, 02/2008, Volume 371, Issue 9610, pp. 395 - 403
Summary Background Chronic immune thrombocytopenic purpura (ITP) is characterised by accelerated platelet destruction and decreased platelet production....
Internal Medicine | AUTOANTIBODIES | ADULT PATIENTS | IN-VITRO | AMG-531 | MEGAKARYOCYTES | CHRONIC ITP | PLATELET DESTRUCTION | SPLENECTOMY | UMCG Approved | THROMBOPOIETIN LEVELS | TGF-BETA-1 | MEDICINE, GENERAL & INTERNAL | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Male | Treatment Outcome | Recombinant Fusion Proteins | Thrombopoietin | Receptors, Fc - therapeutic use | Carrier Proteins - adverse effects | Splenectomy | Platelet Count | Receptors, Fc - administration & dosage | Carrier Proteins - administration & dosage | Purpura, Thrombotic Thrombocytopenic - drug therapy | Purpura, Thrombotic Thrombocytopenic - immunology | Adult | Female | Aged | Carrier Proteins - therapeutic use | Purpura, Thrombotic Thrombocytopenic - blood | Chronic Disease - drug therapy | Thrombocytopenic purpura | Drug therapy | Research | Clinical trials | Blood diseases | Medical treatment | Chronic illnesses
Internal Medicine | AUTOANTIBODIES | ADULT PATIENTS | IN-VITRO | AMG-531 | MEGAKARYOCYTES | CHRONIC ITP | PLATELET DESTRUCTION | SPLENECTOMY | UMCG Approved | THROMBOPOIETIN LEVELS | TGF-BETA-1 | MEDICINE, GENERAL & INTERNAL | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Male | Treatment Outcome | Recombinant Fusion Proteins | Thrombopoietin | Receptors, Fc - therapeutic use | Carrier Proteins - adverse effects | Splenectomy | Platelet Count | Receptors, Fc - administration & dosage | Carrier Proteins - administration & dosage | Purpura, Thrombotic Thrombocytopenic - drug therapy | Purpura, Thrombotic Thrombocytopenic - immunology | Adult | Female | Aged | Carrier Proteins - therapeutic use | Purpura, Thrombotic Thrombocytopenic - blood | Chronic Disease - drug therapy | Thrombocytopenic purpura | Drug therapy | Research | Clinical trials | Blood diseases | Medical treatment | Chronic illnesses
Journal Article
Journal of the American Society of Hypertension, ISSN 1933-1711, 06/2017, Volume 11, Issue 6, pp. 325 - 333.e2
Digital vascular tone and function, as measured by peripheral arterial tonometry (PAT), are associated with cardiovascular risk and events in non-Hispanic...
endothelial function | risk factors | blacks | FLOW-MEDIATED DILATION | BLOOD-PRESSURE | NITRIC-OXIDE PRODUCTION | ARTERIAL COMPLIANCE | INSULIN-RESISTANCE | SHEAR-STRESS | DISEASE | RACE | PERIPHERAL VASCULAR DISEASE | HYPERTENSION | Blood Pressure | Body Mass Index | Age Factors | United States | Humans | Middle Aged | Risk Factors | African Americans | Male | Vasodilation | Endothelium, Vascular - physiology | Arteries - physiology | Fingers | Sex Factors | Cardiovascular Diseases - epidemiology | Heart Rate - physiology | Adult | Female | Aged | Cardiovascular Diseases - diagnosis | Cohort Studies | Manometry - methods
endothelial function | risk factors | blacks | FLOW-MEDIATED DILATION | BLOOD-PRESSURE | NITRIC-OXIDE PRODUCTION | ARTERIAL COMPLIANCE | INSULIN-RESISTANCE | SHEAR-STRESS | DISEASE | RACE | PERIPHERAL VASCULAR DISEASE | HYPERTENSION | Blood Pressure | Body Mass Index | Age Factors | United States | Humans | Middle Aged | Risk Factors | African Americans | Male | Vasodilation | Endothelium, Vascular - physiology | Arteries - physiology | Fingers | Sex Factors | Cardiovascular Diseases - epidemiology | Heart Rate - physiology | Adult | Female | Aged | Cardiovascular Diseases - diagnosis | Cohort Studies | Manometry - methods
Journal Article
Journal of the American Society of Hypertension, ISSN 1933-1711, 05/2017, Volume 11, Issue 5, pp. 258 - 264
Peripheral vascular endothelial dysfunction assessed by digital peripheral arterial tonometry (PAT) has been associated with risk for adverse cardiovascular...
baseline pulse amplitude | reactive hyperemia index | Augmentation index | sub-clinical cardiovascular risk factors | CROSS-SECTIONAL RELATIONS | RISK-FACTORS | CARDIOVASCULAR OUTCOMES | AORTIC STIFFNESS | HYPERTROPHY | BRACHIAL-ARTERY | DISEASE | NITRIC-OXIDE | PERIPHERAL VASCULAR DISEASE | PROGNOSTIC-SIGNIFICANCE | DYSFUNCTION | Blood Pressure | Body Mass Index | Microvessels - physiopathology | United States | Humans | Middle Aged | Risk Factors | Endothelium, Vascular - physiopathology | Pulse | African Americans | Organ Size | Male | Heart Ventricles - diagnostic imaging | Magnetic Resonance Imaging | Female | Aged | Arteries - diagnostic imaging | Heart Ventricles - pathology | Cohort Studies | Hypertrophy, Left Ventricular - diagnostic imaging | Manometry - methods
baseline pulse amplitude | reactive hyperemia index | Augmentation index | sub-clinical cardiovascular risk factors | CROSS-SECTIONAL RELATIONS | RISK-FACTORS | CARDIOVASCULAR OUTCOMES | AORTIC STIFFNESS | HYPERTROPHY | BRACHIAL-ARTERY | DISEASE | NITRIC-OXIDE | PERIPHERAL VASCULAR DISEASE | PROGNOSTIC-SIGNIFICANCE | DYSFUNCTION | Blood Pressure | Body Mass Index | Microvessels - physiopathology | United States | Humans | Middle Aged | Risk Factors | Endothelium, Vascular - physiopathology | Pulse | African Americans | Organ Size | Male | Heart Ventricles - diagnostic imaging | Magnetic Resonance Imaging | Female | Aged | Arteries - diagnostic imaging | Heart Ventricles - pathology | Cohort Studies | Hypertrophy, Left Ventricular - diagnostic imaging | Manometry - methods
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 05/2015, Volume 65, Issue 17, pp. 1721 - 1723
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 08/2018, Volume 11, Issue 1, pp. 101 - 10
Background: Ruxolitinib improves splenomegaly and symptoms in patients with intermediate-2 or high-risk myelofibrosis; however, nearly half develop grade 3/4...
Thrombocytopenia | Ruxolitinib | Janus kinase | Myelofibrosis | Transfusion | Anemia | SURVIVAL | EFFICACY | SAFETY | FOLLOW-UP | INCB018424 | ONCOLOGY | MUTATION | DOUBLE-BLIND | JAK2 | INHIBITOR | HEMATOLOGY | AVAILABLE THERAPY | Drugs | Dosage and administration | Research | Drug therapy | Spleen | Studies | Splenomegaly | Blood platelets | Risk groups | Clinical medicine | Patients | Quality of life | Tumors
Thrombocytopenia | Ruxolitinib | Janus kinase | Myelofibrosis | Transfusion | Anemia | SURVIVAL | EFFICACY | SAFETY | FOLLOW-UP | INCB018424 | ONCOLOGY | MUTATION | DOUBLE-BLIND | JAK2 | INHIBITOR | HEMATOLOGY | AVAILABLE THERAPY | Drugs | Dosage and administration | Research | Drug therapy | Spleen | Studies | Splenomegaly | Blood platelets | Risk groups | Clinical medicine | Patients | Quality of life | Tumors
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 2013, Volume 6, Issue 1, p. 81
Background: Ruxolitinib, a Janus kinase 1 and 2 inhibitor, demonstrated improvements in spleen volume, symptoms, and survival over placebo and best available...
Spleen volume | Total symptom score | Ruxolitinib | Myelofibrosis | Phase II | Janus kinase inhibitor | Platelet count | CRITERIA | DIAGNOSIS | MYELOPROLIFERATIVE NEOPLASMS | INCB018424 | INTERNATIONAL WORKING GROUP | THERAPY | ONCOLOGY | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | INHIBITOR | HEMATOLOGY | Blood Platelets - pathology | Primary Myelofibrosis - drug therapy | Pyrazoles - therapeutic use | Humans | Male | Treatment Outcome | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Janus Kinases - antagonists & inhibitors | Primary Myelofibrosis - blood | Platelet Count | Protein Kinase Inhibitors - therapeutic use | Female | Aged | Pyrazoles - adverse effects | Dose-response relationship (Biochemistry) | Medical research | Pharmacology, Experimental | Analysis | Medicine, Experimental | Aneurysms | Hemoglobin | Glycoproteins | Kidney diseases | Bone marrow | Hospitals | Medical treatment | Colleges & universities
Spleen volume | Total symptom score | Ruxolitinib | Myelofibrosis | Phase II | Janus kinase inhibitor | Platelet count | CRITERIA | DIAGNOSIS | MYELOPROLIFERATIVE NEOPLASMS | INCB018424 | INTERNATIONAL WORKING GROUP | THERAPY | ONCOLOGY | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | INHIBITOR | HEMATOLOGY | Blood Platelets - pathology | Primary Myelofibrosis - drug therapy | Pyrazoles - therapeutic use | Humans | Male | Treatment Outcome | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Janus Kinases - antagonists & inhibitors | Primary Myelofibrosis - blood | Platelet Count | Protein Kinase Inhibitors - therapeutic use | Female | Aged | Pyrazoles - adverse effects | Dose-response relationship (Biochemistry) | Medical research | Pharmacology, Experimental | Analysis | Medicine, Experimental | Aneurysms | Hemoglobin | Glycoproteins | Kidney diseases | Bone marrow | Hospitals | Medical treatment | Colleges & universities
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 65, Issue 17, pp. 1721 - 1723
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 69, Issue 11, pp. e71 - e126
Cardiovascular | Internal Medicine | ACC/AHA Clinical Practice Guideline | limb salvage | antiplatelet agents | critical limb ischemia | peripheral artery disease | smoking cessation | endovascular procedures | bypass surgery | supervised exercise | claudication | acute limb ischemia | ULTRASOUND-ACCELERATED THROMBOLYSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | ANKLE-BRACHIAL INDEX | PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY | RANDOMIZED CONTROLLED-TRIAL | AMERICAN-HEART-ASSOCIATION | DIGITAL-SUBTRACTION-ANGIOGRAPHY | CLINICAL-PRACTICE GUIDELINES | DUAL ANTIPLATELET THERAPY | QUALITY-OF-LIFE
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2/2007, Volume 25, Issue 1, pp. 85 - 94
Background: To evaluate the tolerability and efficacy of nolatrexed in patients with advanced hepatocellular carcinoma. Patients and methods: Forty-eight...
Medicine & Public Health | Phase II clinical trial | Thymitaq | Oncology | Hepatocellular carcinoma | Thymidylate synthase inhibitors | Pharmacology/Toxicology | thymidylate synthase inhibitors | ONCOLOGY | THYMIDYLATE SYNTHASE INHIBITOR | phase II clinical trial | DOXORUBICIN | ADRIAMYCIN | PHARMACOLOGY & PHARMACY | CANCER | hepatocellular carcinoma | CHEMOTHERAPY | Antimetabolites, Antineoplastic - pharmacokinetics | Nausea - chemically induced | Humans | Middle Aged | Quinazolines - pharmacokinetics | Male | Metabolic Clearance Rate | Carcinoma, Hepatocellular - drug therapy | Time Factors | Exanthema - chemically induced | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Drug Administration Schedule | Liver Neoplasms - drug therapy | Treatment Outcome | Quinazolines - blood | Antimetabolites, Antineoplastic - therapeutic use | Quinazolines - therapeutic use | Stomatitis - chemically induced | Antimetabolites, Antineoplastic - adverse effects | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Infusions, Intravenous | Clinical trials | Pharmacology | Liver diseases | Clinical outcomes | Cancer
Medicine & Public Health | Phase II clinical trial | Thymitaq | Oncology | Hepatocellular carcinoma | Thymidylate synthase inhibitors | Pharmacology/Toxicology | thymidylate synthase inhibitors | ONCOLOGY | THYMIDYLATE SYNTHASE INHIBITOR | phase II clinical trial | DOXORUBICIN | ADRIAMYCIN | PHARMACOLOGY & PHARMACY | CANCER | hepatocellular carcinoma | CHEMOTHERAPY | Antimetabolites, Antineoplastic - pharmacokinetics | Nausea - chemically induced | Humans | Middle Aged | Quinazolines - pharmacokinetics | Male | Metabolic Clearance Rate | Carcinoma, Hepatocellular - drug therapy | Time Factors | Exanthema - chemically induced | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Drug Administration Schedule | Liver Neoplasms - drug therapy | Treatment Outcome | Quinazolines - blood | Antimetabolites, Antineoplastic - therapeutic use | Quinazolines - therapeutic use | Stomatitis - chemically induced | Antimetabolites, Antineoplastic - adverse effects | Carcinoma, Hepatocellular - pathology | Survival Analysis | Aged | Infusions, Intravenous | Clinical trials | Pharmacology | Liver diseases | Clinical outcomes | Cancer
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 69, Issue 11, pp. 1465 - 1508
Journal Article